Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid
Masanobu Tsuda, Yuki Moritoki, Zhe-Xiong Lian, et al.
Hepatology (2011) Vol. 55, Iss. 2, pp. 512-521
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis
Gideon M. Hirschfield, M. Eric Gershwin
Annual Review of Pathology Mechanisms of Disease (2013) Vol. 8, Iss. 1, pp. 303-330
Closed Access | Times Cited: 286
The autoimmune basis of alopecia areata: A comprehensive review
Naseeha Islam, Patrick S.C. Leung, Arthur C. Huntley, et al.
Autoimmunity Reviews (2014) Vol. 14, Iss. 2, pp. 81-89
Closed Access | Times Cited: 221
A pilot study of umbilical cord‐derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis
Lifeng Wang, Jin Li, Honghong Liu, et al.
Journal of Gastroenterology and Hepatology (2013) Vol. 28, Iss. S1, pp. 85-92
Closed Access | Times Cited: 176
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses
Gerwyn Morris, Michael Berk, Ken Walder, et al.
BMC Medicine (2015) Vol. 13, Iss. 1
Open Access | Times Cited: 161
Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy
Kelly W. Burak, Mark G. Swain, Tania Santodomino-Garzon, et al.
Canadian Journal of Gastroenterology (2013) Vol. 27, Iss. 5, pp. 273-280
Open Access | Times Cited: 158
The diagnosis of primary biliary cirrhosis
Christopher L. Bowlus, M. Eric Gershwin
Autoimmunity Reviews (2014) Vol. 13, Iss. 4-5, pp. 441-444
Open Access | Times Cited: 150
Novel therapeutic targets in primary biliary cirrhosis
Jessica Dyson, Gideon M. Hirschfield, David H. Adams, et al.
Nature Reviews Gastroenterology & Hepatology (2015) Vol. 12, Iss. 3, pp. 147-158
Closed Access | Times Cited: 115
B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid
Robert P. Myers, Mark G. Swain, Samuel S. Lee, et al.
The American Journal of Gastroenterology (2013) Vol. 108, Iss. 6, pp. 933-941
Closed Access | Times Cited: 113
The challenges of primary biliary cholangitis: What is new and what needs to be done
Benedetta Terziroli Beretta‐Piccoli, Giorgina Mieli‐Vergani, Diego Vergani, et al.
Journal of Autoimmunity (2019) Vol. 105, pp. 102328-102328
Open Access | Times Cited: 106
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Treta Purohit
World Journal of Hepatology (2015) Vol. 7, Iss. 7, pp. 926-926
Open Access | Times Cited: 104
Functional and Structural Features of Cholangiocytes in Health and Disease
Luca Maroni, Haibo Bai, Debolina Ray, et al.
Cellular and Molecular Gastroenterology and Hepatology (2015) Vol. 1, Iss. 4, pp. 368-380
Open Access | Times Cited: 95
Current and potential treatments for primary biliary cholangitis
Raj A. Shah, Kris V. Kowdley
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 5, Iss. 3, pp. 306-315
Closed Access | Times Cited: 88
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
Sho Hasegawa, Masato Yoneda, Yusuke Kurita, et al.
Drugs (2021) Vol. 81, Iss. 10, pp. 1181-1192
Open Access | Times Cited: 72
Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms
Koichi Tsuneyama, Hayato Baba, Yuki Morimoto, et al.
The Journal of Medical Investigation (2017) Vol. 64, Iss. 1.2, pp. 7-13
Open Access | Times Cited: 80
S2k Leitlinie Autoimmune Lebererkrankungen

Zeitschrift für Gastroenterologie (2017) Vol. 55, Iss. 11, pp. 1135-1226
Closed Access | Times Cited: 76
Cholestatic liver diseases: new targets, new therapies
Priscila Santiago, Andrew R. Scheinberg, Cynthia Levy
Therapeutic Advances in Gastroenterology (2018) Vol. 11
Open Access | Times Cited: 73
Primary biliary cholangitis: Old and novel therapy
Annarosa Floreani, Chiara Mangini
European Journal of Internal Medicine (2017) Vol. 47, pp. 1-5
Closed Access | Times Cited: 68
Novel and emerging therapies for cholestatic liver diseases
Jordan Goldstein, Cynthia Levy
Liver International (2018) Vol. 38, Iss. 9, pp. 1520-1535
Open Access | Times Cited: 64
Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial
Amardeep Khanna, Laura Jopson, Denise Howel, et al.
Hepatology (2018) Vol. 70, Iss. 5, pp. 1646-1657
Closed Access | Times Cited: 62
Drug Therapies for Chronic Cholestatic Liver Diseases
Martin Wagner, Peter Fickert
The Annual Review of Pharmacology and Toxicology (2019) Vol. 60, Iss. 1, pp. 503-527
Open Access | Times Cited: 61
The Contribution of B Cells in Autoimmune Liver Diseases
Sarah A. Taylor, David N. Assis, Cara L. Mack
Seminars in Liver Disease (2019) Vol. 39, Iss. 04, pp. 422-431
Open Access | Times Cited: 55
Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease
Andrea Kristina Horst, Kingsley Gideon Kumashie, Katrin Neumann, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 92-111
Open Access | Times Cited: 51
Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
Marlyn J. Mayo
Hepatology (2022) Vol. 76, Iss. 2, pp. 518-531
Closed Access | Times Cited: 35
Unmet clinical need in autoimmune liver diseases
Jessica Dyson, Gwilym J. Webb, Gideon M. Hirschfield, et al.
Journal of Hepatology (2014) Vol. 62, Iss. 1, pp. 208-218
Open Access | Times Cited: 64
Breach of Tolerance: Primary Biliary Cirrhosis
Lifeng Wang, Christopher Chang, M. Eric Gershwin, et al.
Seminars in Liver Disease (2014) Vol. 34, Iss. 03, pp. 297-317
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top